ClinicalTrials.gg
RecruitingNCT07046065Updated Jul 1, 2025

Algorithm-assisted Subjective Refraction Program Dedicated to Children

An interventional study of Non-cycloplegic Objective refraction and Non-cycloplegic conventional subjective refraction in Refractive Assessment, Refractive Disorders and Hyperopia and Myopia, sponsored by Essilor International. Recruiting at 1 site in Portugal. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Essilor International · Not applicable, Interventional, and Screening

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

Current refraction assessment in children is dependent on the Eye Care Specialist and lacks standardization. Essilor has developed new algorithm assisted subjective refraction software dedicated to children of 6-12 years old and suitable for use with Vision-S™ and Vision-R™ phoropters, in addition to existing software.

Two different versions of the software have been developed: the first incorporating only the steps needed to perform an entire subjective refraction process (vA), and the second, identical to the first but incorporating additional steps useful for managing the child's attention and cooperation (vB).

The software performance in terms of subjective refraction results will be compared to a conventional subjective refraction method performed with the Vision-R™700 phoropter in manual mode.

Read the detailed description

The goal of the investigation is to evaluate the accuracy of the Kids refraction software results performed with the phoropters Vision-R™700 and Vision-S™700 compared to the conventional subjective refraction method results performed with Vision-R™700. Phase A of the investigation will focus on the validation of the first version (Kids refraction software vA), and phase B will involve the second version (Kids refraction software vB).

There are two phases in the investigation:

Phase A:

To evaluate the agreement of the subjective refraction results (Sphere, Cylinder, Axis, VA) between the Kids Refraction software vA (randomization between Vision-R or Vision-S devices) results and a conventional subjective refraction (performed with Vision-R), in a non-cycloplegic condition.

Phase B:

To evaluate the agreement of the subjective refraction results (Sphere, Cylinder, Axis, VA) between the Kids Refraction software vB with additional attention and cooperation stages (randomization between Vision-R or Vision-S devices) results and a conventional subjective refraction (performed with Vision-R), in a non-cycloplegic condition.

02

Conditions studied

  • Refractive Assessment
  • Refractive Disorders
  • Hyperopia and Myopia
  • Astigmatism
  • Refractive Error Correction
  • Children

Keywords

  • cycloplegic refraction
  • non-cycloplegic refraction
  • subjective refraction
03

In context

Refractive Errors

420 studies on the registry are indexed under Refractive Errors; 59 are open to participants now.

This study's planned enrollment of 166 is above the median of 76 across 301 interventional studies indexed under Refractive Errors.

Browse Refractive Errors studies →

Lead sponsor

Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 6 and 12 years
  2. Subject able to recognize and name the letters of the Latin alphabet
  3. Pupillary distance (PD) not less than 49mm
  4. Distance refractive error for spherical equivalence (SE) within the range of [-6.00 to +6.00 D] maximum of the two absolute values RE and LE; Cyl ≤ 3.00 D
  5. Monocular Visual acuity ≥ +0.30 LogMAR (0.5 Decimal VA) in each eye at distance
  6. Visual acuity difference \< 0.20 logMAR between right and left eyes at distance

Exclusion criteria

Exclusion Criteria:

  1. Vulnerability of the subject
  2. Amblyopia
  3. Strabismus
  4. Any current or evolving pathology manifested in the eye or the appendages which might have an influence on vision, or interfere with refractive state
  5. Any previous ocular surgery, which might have an influence on vision or interfere with study assessments (e.g. iridectomy, refractive surgery…)
  6. Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.)
  7. Any neurological or speech disorders that might interfere with the ability to understand and answer questions or communicate with the ECP
  8. Any untreated and/or uncontrolled systemic condition which might have an influence on vision or interfere with study assessments
  9. Current use of ocular or systemic medications, which, in the Investigator's opinion, may significantly affect pupil size, accommodation or refractive state
  10. History of myopia control intervention that may affect refractive assessment (e.g., atropine, orthokeratology, rigid gas permeable lenses (RGP) etc.) except myopia control spectacles
  11. of cycloplegia (e.g. high Intra-ocular pressure - more than 22mmHg in either eye, narrow anterior angle, history of allergy to cycloplegic agents or seizures, etc)
  12. Aphakic or pseudoaphakic (intraocular lens),
  13. Prismatic prescription in either Right or Left eye (horizontal or vertical). -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
166 participants (estimated)

Study arms

  • Active comparator
    Validation of the Kids Refraction softwares vA and vB performed with Vision-R™ phoropter

    Measurement of the non-cycloplegic refraction with Vision-R™ phoropter and comparison with the conventional refraction measurement method. Measurement of the cycloplegic refraction with Vision-R™ phoropter and comparison with non-cycloplegic refraction with Vision-R™ phoropter.

    Device: Non-cycloplegic Objective refraction · Device: Non-cycloplegic conventional subjective refraction · Device: Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-R™) · Device: Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-R™) · Device: Cycloplegic subjective refraction (Kids refraction software vA with Vision-R™) · Device: Cycloplegic Objective refraction · Device: Non-cycloplegic Retinoscopy · Device: Cycloplegic retinoscopy

  • Active comparator
    Validation of the Kids Refraction softwares vA and vB performed with Vision-S™ phoropter

    Measurement of the non-cycloplegic refraction with Vision-S™ phoropter and comparison with the conventional refraction measurement method. Measurement of the cycloplegic refraction with Vision-S™ phoropter and comparison with non-cycloplegic refraction with Vision-S™ phoropter.

    Device: Non-cycloplegic Objective refraction · Device: Non-cycloplegic conventional subjective refraction · Device: Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-S™) · Device: Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-S™) · Device: Cycloplegic subjective refraction (Kids refraction software vA with Vision-S™) · Device: Cycloplegic Objective refraction · Device: Non-cycloplegic Retinoscopy · Device: Cycloplegic retinoscopy

Interventions

  • DeviceNon-cycloplegic Objective refraction

    Objective refraction will be measured using an auto-kerato-refractometer/aberrometer without cyclopegia

  • DeviceNon-cycloplegic conventional subjective refraction

    Performed with Vision-R™

  • DeviceNon-cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)

    Performed with Vision-R™

  • DeviceNon-cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)

    Performed with Vision-S™

  • DeviceNon-cycloplegic subjective refraction (Kids refraction software vB with Vision-R™)

    Performed with Vision-R™

  • DeviceNon-cycloplegic subjective refraction (Kids refraction software vB with Vision-S™)

    Performed with Vision-S™

  • DeviceCycloplegic subjective refraction (Kids refraction software vA with Vision-R™)

    Performed with Vision-R™

  • DeviceCycloplegic subjective refraction (Kids refraction software vA with Vision-S™)

    Performed with Vision-S™

  • DeviceCycloplegic Objective refraction

    Objective refraction will be measured using an auto-kerato-refractometer/aberrometer with cyclopegia

  • DeviceNon-cycloplegic Retinoscopy

    Performed with a retinoscope without cycloplegia

  • DeviceCycloplegic retinoscopy

    Performed with a retinoscope with cycloplegia

06

What researchers measure

Primary outcomes

  1. Subjective Sphere (with Kids refraction software vA, with Vision-R™ and with Vision-S™)

    The term "sphere" means that the correction for myopia or hyperopia is spherical, equal in all meridians of the eye. This indicates the amount of lens power, measured in diopters (D), prescribed to correct myopia or hyperopia.

    Time frame: Day 1

  2. Subjective Cylinder (with Kids refraction software vA, with Vision-R™ and with Vision-S™)

    Indicates the amount of lens power for astigmatism, measured in diopters (D) and represents the difference in the greatest and weakest powers of the eye, usually separated by 90 degrees.

    Time frame: Day 1

  3. Subjective Axis (with Kids refraction software vA, with Vision-R™ and with Vision-S™)

    Indicates the orientation of the Cylinder, measured in degrees (°)

    Time frame: Day 1

  4. Subjective Sphere (with Kids refraction software vB, with Vision-R™ and with Vision-S™)

    The term "sphere" means that the correction for myopia or hyperopia is spherical, equal in all meridians of the eye. This indicates the amount of lens power, measured in diopters (D), prescribed to correct myopia or hyperopia.

    Time frame: Six months after Day 1

  5. Subjective Cylinder (with Kids refraction software vB, with Vision-R™ and with Vision-S™)

    Indicates the amount of lens power for astigmatism, measured in diopters (D) and represents the difference in the greatest and weakest powers of the eye, usually separated by 90 degrees.

    Time frame: Six months after Day 1

  6. Subjective Axis (with Kids refraction software vB, with Vision-R™ and with Vision-S™)

    Indicates the orientation of the Cylinder, measured in degrees (°)

    Time frame: Six months after Day 1

  7. Subjective Sphere (with conventional method with Vision-R™)

    The term "sphere" means that the correction for myopia or hyperopia is spherical, equal in all meridians of the eye. This indicates the amount of lens power, measured in diopters (D), prescribed to correct myopia or hyperopia.

    Time frame: Day 1

  8. Subjective Cylinder (with conventional method, with Vision-R™)

    Indicates the amount of lens power for astigmatism, measured in diopters (D) and represents the difference in the greatest and weakest powers of the eye, usually separated by 90 degrees.

    Time frame: Day 1

  9. Subjective Axis (with conventional method, with Vision-R™)

    Indicates the orientation of the Cylinder, measured in degrees (°)

    Time frame: Day 1

  10. Visual acuity (with Kids refraction software vA, with Vision-R™ and with Vision-S™)

    Corrected visual acuity measure with Kids refraction software vA results

    Time frame: From enrollment (Day 1) to the end of the study at 7,5 months

  11. Visual acuity (with Kids refraction software vB, with Vision-R™ and with Vision-S™)

    Corrected visual acuity measure with Kids refraction software vB results

    Time frame: From enrollment (Day 1) to the end of the study at 7,5 months

  12. Visual acuity (with Conventionnal refraction method, with Vision-R™)

    Corrected visual acuity measure with Conventionnal refraction method results

    Time frame: From enrollment (Day 1) to the end of the study at 7,5 months

07

Study locations

1 of 1 sites recruiting
  • Centro de Investigação, Inovação e Ensino Superior (CIIES) de Famalicão
    Vila Nova de Famalicão, 4764-502, Portugal
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no need to share individual anonymized data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 115 industry-sponsored interventional studies with no phase under Refractive Errors, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 7 months is above that.

Counting every sponsor, half of 172 studies reached it within 7 months; a quarter within 2 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jul 1, 2025
StartActual
May 23, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046065
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
May 23, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 1, 2025

Study contacts

Ana Júlia Sousa
Contact
asousa@evidenze.com
+351 21 409 60 79
José Manuel González- Meijome, PhD
principal investigator · Clinical & Experimental Optometry Research Lab Department of Physics (Optometry) - School of Science University of Minho, 4710-057 Gualtar - Braga (Portugal)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion